SEAGULL HEALTH
Your health,We care!
Sunvozertinib features broad-spectrum inhibition, wild-type selectivity, excellent pharmacokinetic properties and definite clinical benefits, and it stands as a representative of domestic innovations in this field.
AuthenticGuaranteeFast DeliveryPrivacy On August 23, 2023, the National Medical Products Administration of China
(NMPA) approved the marketing of Sunvozertinib Tablets for the treatment of
adult patients with locally advanced or metastatic non-small cell lung cancer
(NSCLC) who have confirmed epidermal growth factor receptor (EGFR) exon 20
insertion mutation by testing, and have experienced disease progression during
or after prior platinum-containing chemotherapy, or are intolerant to
platinum-containing chemotherapy.
On August 23, 2023, the National Medical Products Administration (NMPA) granted conditional approval for the marketing of Sunvozertinib Tablets (trade···【Read More】
Update: 29 Jan,2026Source: Haiou HealthViews: 107
Copyright 2024 @ haiouhealth.com All right reserved Seagull health | Bigbear Pharmaceutical | Lucius Pharmaceuticals | 老挝全球药房
